{
  "meta": {
    "title": "60_Obstructive_Lung_Diseases",
    "url": "https://brainandscalpel.vercel.app/60-obstructive-lung-diseases-f16914b5.html",
    "scrapedAt": "2025-11-30T06:57:31.897Z"
  },
  "questions": [
    {
      "id": 66733,
      "choices": [
        {
          "id": 209953,
          "text": "Pneumothorax"
        },
        {
          "id": 209954,
          "text": "Viral pneumonia"
        },
        {
          "id": 209955,
          "text": "Bronchial obstruction"
        },
        {
          "id": 209956,
          "text": "Pleural effusion"
        }
      ],
      "text": "A 70-year-old man and heavy smoker presents with progressive shortness of breath. Other than a Breath sounds are absent on right side of the chest. Percussion of the right chest reveals a dull note with trachea deviated towards right. Which of the following diagnoses is most likely?",
      "unique_key": "Q8544645",
      "question_audio": null,
      "question_video": null,
      "map_id": 34760273,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Bronchial obstruction The most likely diagnosis is bronchial obstruction due to the following reasons: Absence of breath sounds: This can occur in bronchial obstruction, where airflow to the affected lung is blocked, leading to decreased or absent breath sounds on auscultation of the lung. The absence of breath sounds on the right side suggests that the lung is not ventilated properly, likely due to obstruction. Dull percussion: The dull percussion note indicates that there is a solid or fluid substance (like a tumor or mucus) in the chest, or collapse of lung tissue. This is typical of a lobar collapse caused by bronchial obstruction. The obstruction can lead to atelectasis (lung collapse), which would cause this dull percussion. Tracheal deviation: The deviation of the trachea towards the affected side suggests that the lung on that side is collapsed, pulling the trachea towards the affected lung. This is often seen in cases of bronchial obstruction where the blockage causes atelectasis of the lung and mediastinal shift. These findings are most consistent with bronchial obstruction potentially due to a tumor or other obstructive lesion. Incorrect Options: A. Pneumothorax (incorrect): In pneumothorax, there would typically be hyperresonance on percussion (due to air in the pleural space) and absent breath sounds over the affected side. However, tracheal deviation would typically occur towards the opposite side (away from the pneumothorax), not towards the affected side. Therefore, the combination of dull percussion and tracheal deviation towards the affected side is not typical of pneumothorax. B. Viral pneumonia (incorrect): In viral pneumonia, breath sounds would typically be reduced or bronchial in nature, but the percussion note would not be dull in the same way as in bronchial obstruction or pleural effusion. In addition, tracheal deviation is not a typical finding in pneumonia. Pneumonia typically involves diffuse lung involvement rather than localized obstruction with mediastinal shift. D. Pleural effusion (incorrect): In pleural effusion, there would indeed be dullness on percussion and absent breath sounds over the effusion, but the trachea would typically be deviated away from the effusion (towards the unaffected side), not towards the affected side. The tracheal deviation in pleural effusion is due to the mass effect of the fluid collection, and this would lead to a shift away from the affected lung.",
      "correct_choice_id": 209955,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66734,
      "choices": [
        {
          "id": 209957,
          "text": "Emphysema"
        },
        {
          "id": 209958,
          "text": "Asbestosis"
        },
        {
          "id": 209959,
          "text": "Pneumonia"
        },
        {
          "id": 209960,
          "text": "Bronchogenic Carcinoma"
        }
      ],
      "text": "A 74-year-old man is evaluated for a 5-year history of gradually progressive dyspnea and dry cough without wheezing or hemoptysis. For the past 2 years he has had pain and occasional swelling in both knees. He has not had fever or lost weight. He smoked one pack of cigarettes a day from the age of 18 to 60 years. He worked as an roofer for 40 years. Physical examination shows no digital clubbing or cyanosis. Auscultation of the lungs reveals bilateral end-inspiratory crackles. Pulmonary function testing shows: Total lung capacity 67% of predicted Residual volume 72% of predicted FVC 65% of predicted FEV1 75% of predicted FEV1/FVC ratio 89% (Normal) DLCO 52% of predicted His chest radiograph is suggestive of Bilateral lower zone predimonant lesions. Which of the following is the most likely diagnosis?",
      "unique_key": "Q1194116",
      "question_audio": null,
      "question_video": null,
      "map_id": 34102152,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Asbestosis The most likely diagnosis for this 74-year-old man is asbestosis. The patient's history of occupational exposure to asbestos as a roofer for 40 years, along with his gradually progressive dyspnea, dry cough, and bilateral end-inspiratory crackles, are all consistent with asbestosis, a type of interstitial lung disease (ILD) caused by inhalation of asbestos fibers. The radiographic finding of bilateral lower zone predominant lesions and the absence of other significant symptoms such as fever, weight loss, or hemoptysis further support this diagnosis. The presence of knee pain and occasional swelling may suggest a connection to an asbestos-related condition, possibly a type of arthropathy that can occur in patients with chronic asbestos exposure. Additionally, asbestosis typically manifests decades after exposure, often in individuals with a significant history of occupational exposure. Explanation for the incorrect options: A. Emphysema (incorrect): Emphysema is a condition primarily caused by smoking, which results in the destruction of the alveolar walls and airway enlargement, leading to progressive dyspnea and cough. However, emphysema typically presents with wheezing and increased resonance on chest percussion, which is not described in this case. The patient has a history of smoking, but his symptoms (especially the bilateral end-inspiratory crackles and lower zone predominant lesions) are more consistent with an interstitial lung disease like asbestosis rather than emphysema. Emphysema would also not explain the patient's knee pain and swelling. C. Pneumonia (incorrect): Pneumonia usually presents with acute symptoms such as fever, productive cough, and chest pain, which are not present in this case. The patient has a 5-year history of progressively worsening dyspnea without any acute infectious symptoms like fever or purulent sputum, making pneumonia less likely. The chest radiograph findings in pneumonia would typically show localized consolidation rather than bilateral lower zone predominant lesions. D. Bronchogenic carcinoma (incorrect): While bronchogenic carcinoma (lung cancer) can present with dyspnea and cough, the absence of symptoms such as weight loss, hemoptysis, or a focal mass on radiograph makes it less likely in this case. Lung cancer typically presents with abnormal findings on a chest radiograph, often showing a solitary mass or nodule, which is not described here. The lower zone predominant lesions and end-inspiratory crackles are more characteristic of interstitial lung disease, such as asbestosis, rather than lung cancer.",
      "correct_choice_id": 209958,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66735,
      "choices": [
        {
          "id": 209961,
          "text": "Myasthenia gravis"
        },
        {
          "id": 209962,
          "text": "Asthma"
        },
        {
          "id": 209963,
          "text": "Bronchiectasis"
        },
        {
          "id": 209964,
          "text": "Chronic bronchitis"
        }
      ],
      "text": "All of the following are typically characterized as an obstructive lung disease EXCEPT:",
      "unique_key": "Q1025054",
      "question_audio": null,
      "question_video": null,
      "map_id": 34360615,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Myasthenia gravis Myasthenia gravis is a neuromuscular disorder that affects the muscles' ability to contract, rather than a primary lung disease. It is characterized by muscle weakness, which can involve the respiratory muscles, leading to respiratory failure in severe cases. While respiratory complications can arise from myasthenia gravis, it is not considered an obstructive lung disease. Obstructive lung diseases are primarily diseases where airflow is impeded, such as in asthma, bronchiectasis, and chronic bronchitis. Explanation for the incorrect responses: B. Asthma (incorrect): Asthma is a classic obstructive lung disease characterized by reversible airflow obstruction. This obstruction is caused by inflammation and bronchoconstriction of the airways, which leads to wheezing, dyspnea, and cough. Asthma results in a decreased FEV1 (forced expiratory volume in one second) and increased residual volume, both indicators of obstructive lung disease. C. Bronchiectasis (incorrect): Bronchiectasis is another obstructive lung disease. It is characterized by permanent dilation and destruction of the bronchi, often resulting from chronic infections, inflammation, or other conditions that lead to airflow obstruction. This obstruction can cause recurrent infections, productive cough, and dyspnea, all typical symptoms of obstructive lung diseases. D. Chronic bronchitis (incorrect): Chronic bronchitis, part of chronic obstructive pulmonary disease (COPD), is a classic obstructive lung disease. It is characterized by persistent inflammation of the bronchi, leading to excessive mucus production and airway narrowing. Patients with chronic bronchitis typically present with productive cough, wheezing, and shortness of breath, all indicative of an obstructive pattern on pulmonary function testing (reduced FEV1 and FEV1/FVC ratio).",
      "correct_choice_id": 209961,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66736,
      "choices": [
        {
          "id": 209965,
          "text": "H.influenza"
        },
        {
          "id": 209966,
          "text": "S. aureus"
        },
        {
          "id": 209967,
          "text": "Klebsiella"
        },
        {
          "id": 209968,
          "text": "Mycoplasma"
        }
      ],
      "text": "Most common bacterial cause implicated in AE COPD is",
      "unique_key": "Q4352749",
      "question_audio": null,
      "question_video": null,
      "map_id": 34135081,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) H. influenza. Haemophilus influenzae is the most common bacterial pathogen implicated in exacerbations of chronic obstructive pulmonary disease (COPD). This bacterium is frequently found in the respiratory tracts of COPD patients and is a major cause of bacterial infections in these individuals. It can lead to worsening of symptoms and increased inflammation in the airways, which results in an exacerbation of COPD. The high incidence of H. influenzae infections in COPD exacerbations makes it the most common bacterial cause. Incorrect Options: (B) S. aureus: Staphylococcus aureus is another potential pathogen in COPD exacerbations, but it is less common than H. influenzae. S. aureus, especially methicillin-resistant Staphylococcus aureus (MRSA), can cause severe infections, particularly in hospitalized or critically ill COPD patients. However, it is not the most frequent cause of exacerbations in the general COPD population. (C) Klebsiella: Klebsiella pneumoniae can also cause infections in COPD patients, but it is not the most common pathogen in acute exacerbations. Klebsiella tends to be associated with more severe, hospital-acquired infections, particularly in patients with significant underlying disease or immunocompromise. It is less frequently isolated compared to H. influenzae in the context of COPD exacerbations. (D) Mycoplasma: Mycoplasma pneumoniae is an atypical pathogen that can cause respiratory infections, but it is generally not the most common bacterial cause of COPD exacerbations. It is more often implicated in community-acquired pneumonia in otherwise healthy individuals, rather than in exacerbations of chronic respiratory conditions like COPD.",
      "correct_choice_id": 209965,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66737,
      "choices": [
        {
          "id": 209969,
          "text": "Observation"
        },
        {
          "id": 209970,
          "text": "Administration of high-?ow oxygen"
        },
        {
          "id": 209971,
          "text": "Simple needle aspiration"
        },
        {
          "id": 209972,
          "text": "Insertion of a chest tube"
        }
      ],
      "text": "A 58-year-old male smoker with a smoking history of 50 pack-years presents to the emergencydepartment after an episode of acute chest pain and shortness of breath. On physical examination, there ismarked reduction of the breath sounds in the left hemithorax. His chest radiograph is shown below. Recentlung function tests had revealed an FVC of 70% predicted, an FEV1 of 45% predicted What is the most appropriate next step in the management of this patient?<p><img src=\"https://d2enu63wt1sf3u.cloudfront.net/course_file_meta/1727293q72medrespirtry.jpg\" alt=\"Question Image\"></p>",
      "unique_key": "Q9440300",
      "question_audio": null,
      "question_video": null,
      "map_id": 34760879,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Insertion of a chest tube. This patient, with a significant smoking history and reduced lung function (suggestive of chronic obstructive pulmonary disease, or COPD), presents with acute chest pain and shortness of breath along with a reduced breath sounds on the left side, which is highly suggestive of a spontaneous pneumothorax. Given the patient's COPD and reduced lung function (as indicated by the FEV1 of 45% predicted), the most appropriate next step in the management of a pneumothorax is the insertion of a chest tube. This is especially important in a patient with significant lung disease, where a large pneumothorax or a tension pneumothorax can rapidly lead to hemodynamic instability. A chest tube will allow for the re-expansion of the lung and prevent further complications. Why Other Options Are Incorrect: (A) Observation: Observation may be appropriate for small, stable pneumothoraces in otherwise healthy patients. However, this patient has significant risk factors (a long history of smoking and lung disease) and a reduced FVC and FEV1, indicating compromised lung function. Given the size of the pneumothorax and his symptoms (chest pain and shortness of breath), this patient likely requires more aggressive intervention, such as a chest tube, rather than simple observation. (B) Administration of high-flow oxygen: While administering high-flow oxygen can help improve the absorption of a pneumothorax and may be used in some cases of small pneumothorax, it is not sufficient as the sole treatment, especially in this patient with a significant underlying lung disease. Oxygen may reduce the size of a small pneumothorax, but it will not resolve a large or symptomatic one, which this patient likely has. A chest tube is the most appropriate intervention for a significant pneumothorax. (C) Simple needle aspiration: Needle aspiration may be considered in some cases of primary spontaneous pneumothorax or when the pneumothorax is small and uncomplicated. However, for a patient with significant symptoms, underlying lung disease (COPD), and likely a large pneumothorax, a chest tube insertion is preferred over needle aspiration. In addition, needle aspiration carries a risk of worsening the pneumothorax if not done correctly, and it is less reliable for ensuring complete resolution compared to a chest tube.",
      "correct_choice_id": 209972,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66738,
      "choices": [
        {
          "id": 209973,
          "text": "Alveolar sac"
        },
        {
          "id": 209974,
          "text": "Terminal bronchiole"
        },
        {
          "id": 209975,
          "text": "Alveolar duct"
        },
        {
          "id": 209976,
          "text": "Respiratory bronchiole"
        }
      ],
      "text": "Which of the following structures in the lung is likely to be affected the most in a patient who smoked a pack and half of cigarettes per day for 30 years and developed entrilobularemphysema",
      "unique_key": "Q5265381",
      "question_audio": null,
      "question_video": null,
      "map_id": 34829347,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Respiratory bronchiole. In centrilobular emphysema, which is commonly associated with smoking, the respiratory bronchioles are the primary structures affected. This type of emphysema primarily involves the central or proximal parts of the acinus (the smallest functional unit of the lung), which includes the respiratory bronchioles and the surrounding alveolar ducts and alveoli. The damage occurs due to the inflammatory response caused by the inhalation of toxic substances in cigarette smoke, leading to the destruction of the walls of the respiratory bronchioles. This destruction reduces the ability of the bronchioles to support the surrounding alveolar structures, leading to airflow obstruction and impaired gas exchange. In this patient, who has a long history of smoking (30 years at a pack and a half per day), centrilobular emphysema is the most likely type of emphysema, and the respiratory bronchioles will be the most affected due to the toxic effects of smoking on these structures. Why Other Options Are Incorrect: (A) Alveolar sac: The alveolar sac is part of the distal acinus and includes the alveolar sacs and alveoli. In centrilobular emphysema, the damage typically occurs in the proximal parts of the acinus (primarily the respiratory bronchioles), not in the alveolar sacs. However, in panlobular emphysema, which affects the entire acinus, the alveolar sacs and alveoli would be more affected. (B) Terminal bronchiole: The terminal bronchioles are the smallest airways that do not have alveoli. While smoking-related emphysema involves the bronchioles, in centrilobular emphysema, the damage is most significant in the respiratory bronchioles, which have small alveoli attached to them. The terminal bronchioles are generally not as directly involved in the initial stages of centrilobular emphysema. (C) Alveolar duct: The alveolar ducts are part of the distal airways, just before the alveolar sacs and alveoli. While panlobular emphysema may affect the alveolar ducts, in centrilobular emphysema, the damage is more localized to the respiratory bronchioles. The alveolar ducts are typically spared or affected later in the disease process, whereas the respiratory bronchioles are the first structures to show signs of destruction.",
      "correct_choice_id": 209976,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66739,
      "choices": [
        {
          "id": 209977,
          "text": "Fvc/Fev1 < 0.7"
        },
        {
          "id": 209978,
          "text": "Fev1/Fvc< 0.7"
        },
        {
          "id": 209979,
          "text": "Fev1/Fvc> 0.7"
        },
        {
          "id": 209980,
          "text": "Fev1/Fvc< 0.9"
        }
      ],
      "text": "Obstructive lung disease is diagnosed if",
      "unique_key": "Q2817429",
      "question_audio": null,
      "question_video": null,
      "map_id": 34954041,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) FEV1/FVC 0.7: This option suggests that an FEV1/FVC ratio greater than 0.7 indicates obstructive lung disease, but this is not true. In healthy individuals, the FEV1/FVC ratio is typically greater than 0.7, and an FEV1/FVC ratio above this value does not indicate obstruction. An FEV1/FVC ratio of greater than 0.7 usually points to normal lung function or a restrictive pattern in lung disease. (D) FEV1/FVC < 0.9: While a FEV1/FVC ratio of less than 0.9 may indicate some lung function impairment, it is not a definitive diagnostic criterion for obstructive lung disease. A ratio of < 0.9 could be seen in various contexts, but the cutoff for obstructive lung disease is < 0.7. Therefore, this option is too broad and does not specifically diagnose obstruction.",
      "correct_choice_id": 209978,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66740,
      "choices": [
        {
          "id": 209981,
          "text": "Pan acinar emphysema seen in alpha 1 AT deficiency"
        },
        {
          "id": 209982,
          "text": "Centri acinar emphysema is seen in smokers"
        },
        {
          "id": 209983,
          "text": "Pan acinar emphysema commonly involves upper lobes"
        },
        {
          "id": 209984,
          "text": "Centriacinar emphysema involves upper lobes and superior segment lower lobes"
        }
      ],
      "text": "Which of the following is false ?",
      "unique_key": "Q3233729",
      "question_audio": null,
      "question_video": null,
      "map_id": 34696385,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Pan acinar emphysema commonly involves upper lobes. Pan acinar emphysema is more commonly seen in alpha-1 antitrypsin (alpha-1 AT) deficiency, and it typically affects the lower lobes of the lungs. In contrast to centrilobular emphysema, which is more common in smokers and involves the upper lobes, pan acinar emphysema affects the entire acinus uniformly, including both the proximal and distal parts of the acinus. In alpha-1 AT deficiency, the lower lobes are more severely affected, making option C false. Why Other Options Are Correct: (A) Pan acinar emphysema seen in alpha 1 AT deficiency: This statement is true. Pan acinar emphysema is indeed a hallmark of alpha-1 antitrypsin (alpha-1 AT) deficiency, a genetic disorder where a deficiency of alpha-1 antitrypsin leads to lung tissue damage and emphysema. This type of emphysema usually affects the lower lobes. (B) Centriacinar emphysema is seen in smokers: This statement is true. Centriacinar emphysema is most commonly associated with smoking and primarily affects the upper lobes of the lungs. It involves the central portions of the acinus (i.e., the respiratory bronchioles) and is characterized by a patchy distribution. (D) Centriacinar emphysema involves upper lobes and superior segment lower lobes: This statement is true. Centriacinar emphysema typically affects the upper lobes, especially the posterior portions and the superior segments of the lower lobes. This type of emphysema is seen more frequently in smokers, and it usually starts in the central parts of the acinus, notably around the bronchioles.",
      "correct_choice_id": 209983,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66741,
      "choices": [
        {
          "id": 209985,
          "text": "PDE4 inhibitor"
        },
        {
          "id": 209986,
          "text": "Anti inflammatory properties"
        },
        {
          "id": 209987,
          "text": "Acutebronchodilatory effect"
        },
        {
          "id": 209988,
          "text": "Causes weight loss"
        }
      ],
      "text": "Which of the following regarding Roflumilast is false ?",
      "unique_key": "Q9934647",
      "question_audio": null,
      "question_video": null,
      "map_id": 34736978,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Acute bronchodilatory effect. Roflumilast is a phosphodiesterase 4 (PDE4) inhibitor. It has anti-inflammatory properties and is primarily used as a long-term treatment for chronic obstructive pulmonary disease (COPD). However, it does not have an acute bronchodilatory effect. This means that Roflumilast is not used for quick relief during asthma attacks or acute exacerbations of COPD. It works by reducing inflammation and improving lung function over a prolonged period but does not provide immediate relief, unlike short-acting bronchodilators. Why Other Options Are Correct: (A) PDE4 inhibitor: This statement is true. Roflumilast is a phosphodiesterase 4 (PDE4) inhibitor, which works by blocking the breakdown of cyclic AMP (cAMP). This helps reduce inflammation in the lungs, making it useful for patients with chronic respiratory conditions like COPD. (B) Anti-inflammatory properties: This statement is true. Roflumilast has anti-inflammatory effects, which reduce inflammation in the airways and help prevent exacerbations in COPD. It is particularly effective in reducing neutrophilic inflammation and improving lung function over time. (D) Causes weight loss: This statement is true. One of the potential side effects of Roflumilast is weight loss, particularly in patients who have severe COPD. The exact mechanism is not entirely understood, but it is thought to be related to the drug's action on metabolism and inflammatory pathways.",
      "correct_choice_id": 209987,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66742,
      "choices": [
        {
          "id": 209989,
          "text": "Indicated if Resting PaO 2 of < 65 mmHg"
        },
        {
          "id": 209990,
          "text": "Indicated if Resting PaO 2 of 56-59 mmHg with evidence of end-organ dysfunction such as pulmonary hypertension"
        },
        {
          "id": 209991,
          "text": "Oxygen should be prescribed to hypoxemic patients, with a target SpO2 between 94 - 98%."
        },
        {
          "id": 209992,
          "text": "Supplemental O2 did not demonstrate decrease mortality rates in patients with COPD"
        }
      ],
      "text": "True regarding 02 therapy in COPD",
      "unique_key": "Q4168590",
      "question_audio": null,
      "question_video": null,
      "map_id": 34995789,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Indicated if Resting PaO2 of 56-59 mmHg with evidence of end-organ dysfunction such as pulmonary hypertension. In chronic obstructive pulmonary disease (COPD), oxygen therapy is typically indicated when there is severe hypoxemia. According to clinical guidelines, if a patient’s resting PaO2 is between 56-59 mmHg, oxygen therapy is recommended if there is evidence of end-organ dysfunction, such as pulmonary hypertension, cor pulmonale, or polycythemia. These complications suggest that the tissues are not receiving adequate oxygen, and supplemental oxygen can help reduce the strain on the heart and improve overall oxygenation. Why Other Options Are Incorrect: (A) Indicated if Resting PaO2 of < 65 mmHg: While oxygen therapy is indeed indicated for patients with PaO2 < 65 mmHg, it is not the only criterion. The threshold of 65 mmHg is generally used in less severe cases or for patients who do not have significant end-organ dysfunction. For patients with PaO2 between 56-59 mmHg, the presence of complications (like pulmonary hypertension) becomes a determining factor, which is why (B) is more accurate. (C) Oxygen should be prescribed to hypoxemic patients, with a target SpO2 between 94 - 98%: This statement is incorrect in the context of COPD. For COPD patients with chronic respiratory failure, the recommended target for SpO2 is generally 88-92% rather than 94-98%, to avoid oxygen-induced hypercapnia. Higher oxygen levels can suppress the respiratory drive in these patients, leading to respiratory acidosis. (D) Supplemental O2 did not demonstrate decrease mortality rates in patients with COPD: This statement is false. Studies have shown that long-term oxygen therapy does, in fact, reduce mortality rates in patients with severe COPD who have chronic hypoxemia. It improves survival, reduces the risk of complications, and helps maintain oxygen levels at a safer range for these patients.",
      "correct_choice_id": 209990,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66743,
      "choices": [
        {
          "id": 209993,
          "text": "Breathing index"
        },
        {
          "id": 209994,
          "text": "Airflow Obstruction"
        },
        {
          "id": 209995,
          "text": "Dyspnea"
        },
        {
          "id": 209996,
          "text": "Exercise capacity"
        }
      ],
      "text": "Which of the following is not a indicator of BODE score ?",
      "unique_key": "Q7905776",
      "question_audio": null,
      "question_video": null,
      "map_id": 34876690,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Breathing index. The BODE score is a multidimensional grading system used to assess the severity of chronic obstructive pulmonary disease (COPD) and to predict mortality and prognosis in patients. The BODE score is based on the following four key indicators: B - Body mass index (BMI): A measure of the patient's nutritional status. O - Airflow Obstruction: Assessed by forced expiratory volume in 1 second (FEV1). D - Dyspnea: Assessed by the Modified Medical Research Council (mMRC) Dyspnea Scale. E - Exercise capacity: Assessed by the 6-minute walk test (6MWT), which measures the distance the patient can walk in 6 minutes. Therefore, \"Breathing index\" is not a component of the BODE score, making it the correct answer. Why Other Options Are Incorrect: (B) Airflow Obstruction: This is a key component of the BODE score. Airflow obstruction is measured using FEV1, which quantifies the severity of lung function impairment in COPD patients. The lower the FEV1, the worse the prognosis. (C) Dyspnea: Dyspnea (shortness of breath) is another important part of the BODE score. It is assessed using the Modified Medical Research Council (mMRC) Dyspnea Scale to determine the level of difficulty a patient experiences with breathing. (D) Exercise Capacity: Exercise capacity is a crucial factor in the BODE score, assessed by the 6-minute walk test (6MWT). This test measures the maximum distance a patient can walk in 6 minutes and helps to evaluate functional capacity and prognosis in COPD patients.",
      "correct_choice_id": 209993,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66744,
      "choices": [
        {
          "id": 209997,
          "text": "FEV1 < 80 % Predicted"
        },
        {
          "id": 209998,
          "text": "FEV1 < 60 % Predicted"
        },
        {
          "id": 209999,
          "text": "FEV1 < 40 % Predicted"
        },
        {
          "id": 210000,
          "text": "FEV1 < 30 % Predicted"
        }
      ],
      "text": "Following comes under very severe COPD according to GOLD staging of COPD",
      "unique_key": "Q3370174",
      "question_audio": null,
      "question_video": null,
      "map_id": 34023115,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) FEV1 < 30% Predicted. According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) staging, very severe COPD is classified when FEV1 (forced expiratory volume in 1 second) is less than 30% of the predicted value. This stage represents GOLD Stage 4, which is the most severe form of COPD, often associated with significant impairment in lung function, and a high risk for respiratory failure and exacerbations. Why Other Options Are Incorrect: (A) FEV1 < 80% Predicted: An FEV1 < 80% predicted corresponds to GOLD Stage 1 (Mild COPD), where the patient experiences minimal symptoms and may not be aware of airflow limitation. This does not fall under the category of very severe COPD. (B) FEV1 < 60% Predicted: An FEV1 < 60% predicted corresponds to GOLD Stage 2 (Moderate COPD). While this stage represents moderate impairment, it does not meet the criteria for very severe COPD. (C) FEV1 < 40% Predicted: An FEV1 < 40% predicted is classified as GOLD Stage 3 (Severe COPD), which is a more advanced stage than moderate but still not as severe as GOLD Stage 4.",
      "correct_choice_id": 210000,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66745,
      "choices": [
        {
          "id": 210001,
          "text": "Chest Xray"
        },
        {
          "id": 210002,
          "text": "Spirometry"
        },
        {
          "id": 210003,
          "text": "CT chest"
        },
        {
          "id": 210004,
          "text": "BODE index"
        }
      ],
      "text": "Current definitive test for establishing the presence or absence of emphysema is",
      "unique_key": "Q3679496",
      "question_audio": null,
      "question_video": null,
      "map_id": 34042554,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) CT chest. The current definitive test for establishing the presence or absence of emphysema is a CT chest (computed tomography of the chest). CT scanning is highly sensitive and can visualize the structural damage associated with emphysema, such as lung hyperinflation and parenchymal destruction. It can also identify bullae, which are characteristic of emphysema. This test provides a clear and detailed view of the lungs and is the most reliable imaging method to confirm emphysema, even in the absence of symptoms. Why Other Options Are Incorrect: (A) Chest X-ray: A chest X-ray is often used in the initial assessment of suspected emphysema, but it is not definitive. It can show signs suggestive of emphysema, such as hyperinflation and flattened diaphragms, but it lacks the sensitivity and specificity of a CT chest. Chest X-rays may miss early or mild emphysema and do not provide the detailed information necessary for diagnosis. (B) Spirometry: Spirometry is an essential tool for diagnosing COPD (which includes emphysema) by measuring lung function, specifically the FEV1 and FVC. While it is useful for assessing airflow obstruction and the degree of functional impairment, spirometry does not directly assess structural lung damage or confirm the presence of emphysema. It is valuable in diagnosing COPD, but not in definitively diagnosing emphysema. (D) BODE index: The BODE index is a composite score that assesses BMI, airflow obstruction, dyspnea, and exercise capacity to predict the prognosis and severity of COPD. While it is useful for assessing disease progression and predicting mortality in COPD patients, it does not directly diagnose or establish the presence of emphysema. The BODE index is more of a prognostic tool rather than a diagnostic test.",
      "correct_choice_id": 210003,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66746,
      "choices": [
        {
          "id": 210005,
          "text": "Expiratory wheezing"
        },
        {
          "id": 210006,
          "text": "Clubbing"
        },
        {
          "id": 210007,
          "text": "Hypercapnia"
        },
        {
          "id": 210008,
          "text": "Right heart failure"
        }
      ],
      "text": "Which of the following is not a feature of COPD?",
      "unique_key": "Q9137831",
      "question_audio": null,
      "question_video": null,
      "map_id": 34320920,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Clubbing. Clubbing is not typically a feature of COPD. While clubbing can be associated with various respiratory conditions, including interstitial lung diseases or lung malignancies, it is not a common finding in chronic obstructive pulmonary disease (COPD). Clubbing refers to the bulbous enlargement of the tips of the fingers and toes and is usually seen in conditions that cause long-term oxygen deprivation or chronic hypoxia, such as cystic fibrosis or bronchiectasis. Why Other Options Are Correct: (A) Expiratory wheezing: Expiratory wheezing is a hallmark symptom of COPD, particularly during exacerbations. It occurs due to airflow limitation and bronchoconstriction, which are common in COPD. The narrowing of the airways leads to turbulent airflow, resulting in the characteristic wheezing sound during expiration. (C) Hypercapnia: Hypercapnia (elevated levels of carbon dioxide in the blood) is a common feature of advanced COPD. Due to the impaired gas exchange and reduced ventilation in COPD, carbon dioxide can accumulate in the blood. This is particularly true in patients with severe disease or during exacerbations, when respiratory failure can occur. (D) Right heart failure: Right heart failure (also known as cor pulmonale) is a common complication of chronic COPD. As the disease progresses, the chronic hypoxia and pulmonary hypertension can lead to increased pressure in the pulmonary arteries. This causes the right side of the heart to work harder to pump blood through the lungs, ultimately resulting in right heart failure.",
      "correct_choice_id": 210006,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66747,
      "choices": [
        {
          "id": 210009,
          "text": "Corticosteroids"
        },
        {
          "id": 210010,
          "text": "Oxygen"
        },
        {
          "id": 210011,
          "text": "Bronchodilators"
        },
        {
          "id": 210012,
          "text": "Theophylline"
        }
      ],
      "text": "The only pharmacologic therapy demonstrated to unequivocally decrease mortality rates in patients with COPD",
      "unique_key": "Q1044016",
      "question_audio": null,
      "question_video": null,
      "map_id": 34345112,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Oxygen. Oxygen therapy is the only pharmacologic treatment that has been unequivocally shown to decrease mortality rates in patients with chronic obstructive pulmonary disease (COPD), particularly in those with severe hypoxemia. Long-term oxygen therapy (LTOT) has been proven to improve survival, quality of life, and exercise capacity in these patients. It is recommended for patients who have a resting PaO2 < 55 mmHg or an oxygen saturation (SpO2) < 88%, especially in the presence of pulmonary hypertension or cor pulmonale. Why Other Options Are Incorrect: (A) Corticosteroids: While inhaled corticosteroids (ICS) can be effective in reducing inflammation and controlling symptoms in COPD, particularly in patients with frequent exacerbations, they do not have a direct effect on mortality. ICS is often used in combination with bronchodilators for better control, but they do not unequivocally reduce mortality. (C) Bronchodilators: Bronchodilators (e.g., beta-agonists, anticholinergics) are essential for symptom relief and improving airflow in COPD patients. They help in reducing dyspnea, improving exercise tolerance, and decreasing exacerbations. However, they do not directly decrease mortality rates. Their primary role is in improving quality of life and lung function. (D) Theophylline: Theophylline is a methylxanthine that has bronchodilator effects and can be used as an adjunct in COPD treatment, particularly when other therapies are not sufficient. However, it has limited benefit in terms of mortality reduction and is generally reserved for specific cases. It also carries a risk of side effects like toxicity and cardiovascular issues, making it less favored for routine use in COPD management.",
      "correct_choice_id": 210010,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66748,
      "choices": [
        {
          "id": 210013,
          "text": "Antibiotics"
        },
        {
          "id": 210014,
          "text": "Home oxygen"
        },
        {
          "id": 210015,
          "text": "Inhaled Tiotropium"
        },
        {
          "id": 210016,
          "text": "Inhaled steroids"
        }
      ],
      "text": "A 75-year-old long-term male smoker comes to OPD with increasing dyspnea when walking, especially upstairs. The patient had been a smoker of one pack/day for 50 years. He quit 2 years ago. This is the first time he has had a decrease in exercise tolerance as he could walk two to three blocks before becoming short of breath. There is No cough, no sputum, no fever No weight loss. BP: 110/70 mm Hg; Pulse: 64 beats/minute; Temperature: 98°F; R:12 breaths/minute Chest: ronchi present, no rales, no rhonchi Cardiovascular: no murmurs Extremities: no edema. PFT- FEV1/FVC < 0.7,FEV1-70% of predicted value, FVC-normal. What will be next line treatment for the patient",
      "unique_key": "Q3746846",
      "question_audio": null,
      "question_video": null,
      "map_id": 34020422,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Inhaled Tiotropium. This 75-year-old smoker presents with increasing dyspnea on exertion, particularly when walking upstairs, and a history of long-term smoking (50 pack-years), which are risk factors for chronic obstructive pulmonary disease (COPD). The pulmonary function test (PFT) shows a reduced FEV1/FVC ratio (<0.7) and a reduced FEV1 (70% of predicted), which indicates airflow obstruction characteristic of COPD. The next appropriate step in managing this patient is to initiate bronchodilator therapy, and inhaled tiotropium, a long-acting anticholinergic, is a first-line treatment for COPD. It helps reduce symptoms, improve lung function, and decrease the frequency of exacerbations by relaxing the airway muscles and improving airflow. Incorrect Options: A. Antibiotics: This patient does not show signs of an infection (e.g., no fever, cough, or sputum production), so antibiotics are not indicated. Antibiotics are used in COPD patients primarily for treating acute exacerbations due to bacterial infections, but they are not appropriate in the absence of such signs. B. Home oxygen: Oxygen therapy is indicated in patients with COPD who have chronic hypoxemia (PaO2 < 55 mm Hg or SpO2 < 88%), especially if they also have pulmonary hypertension or cor pulmonale. However, this patient does not appear to be hypoxemic based on his stable vitals and symptoms, making home oxygen unnecessary at this stage. D. Inhaled steroids: Inhaled corticosteroids (ICS) are commonly used in COPD patients who have frequent exacerbations or a significant eosinophilic component to their inflammation. However, the primary treatment for this patient at this stage, with moderate COPD and without frequent exacerbations, would be inhaled bronchodilators like tiotropium, not steroids. ICS are often combined with long-acting beta-agonists (LABAs) but are not first-line on their own for this patient.",
      "correct_choice_id": 210015,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/5817411705127486/5817411705127486.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/5817411705127486/5817411705127486.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66749,
      "choices": [
        {
          "id": 210017,
          "text": "Increased fibrosis of lungs"
        },
        {
          "id": 210018,
          "text": "Increased residual volume"
        },
        {
          "id": 210019,
          "text": "Decreased compliance"
        },
        {
          "id": 210020,
          "text": "Decreased FEV1"
        }
      ],
      "text": "A 60 year old smoker c/o dyspnea on exertion with cough and mucoid sputum for 2 years. He got pulmonary functions test done which shows FEV1/FVC as 0.65, FVC is 90 % of predicted value.FEV1 doesn’t improve after beta agonist inhaler. A diagnosis of COPD is made on PFT findings. On examination the shape of the chest is abnormal as shown in the figure. What is the pathophysiologic basis of this chest deformity?<p><img src=\"https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/Resp-DQBCV2021.jpg\" alt=\"Question Image\"></p>",
      "unique_key": "Q1729782",
      "question_audio": null,
      "question_video": null,
      "map_id": 34794254,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Increased residual volume. The patient's history of dyspnea on exertion, cough with mucoid sputum, and the PFT findings (FEV1/FVC ratio of 0.65 and no improvement after a beta agonist) are consistent with chronic obstructive pulmonary disease (COPD). COPD is characterized by airflow limitation, which leads to air trapping and an increase in residual volume (RV), the amount of air remaining in the lungs after exhalation. The physical sign of an abnormal chest shape, particularly a \"barrel-shaped\" chest, is due to hyperinflation and air trapping, where the lungs remain inflated due to the increased residual volume. This results in an increased anterior-posterior diameter of the chest and an overall change in chest shape. Incorrect Options: A. Increased fibrosis of lungs: Fibrosis typically occurs in restrictive lung diseases, not in obstructive diseases like COPD. In COPD, the main issue is airway obstruction and air trapping, not fibrosis. While COPD can involve some degree of lung tissue damage, fibrosis is not the primary pathophysiologic cause of the chest deformity seen in this patient. C. Decreased compliance: Decreased lung compliance refers to the stiffness of the lungs, which is a characteristic of restrictive lung diseases such as interstitial lung disease or pulmonary fibrosis. In COPD, compliance is generally increased in the early stages due to hyperinflation and loss of lung elasticity. Decreased compliance would lead to difficulty in expanding the lungs, but it is not the primary cause of the chest deformity in this patient. D. Decreased FEV1: While a decreased FEV1 is a hallmark of COPD and contributes to the overall airflow limitation, it does not directly cause the chest shape deformity. The abnormal chest shape is more related to air trapping (increased RV) than to the reduction in FEV1 itself.",
      "correct_choice_id": 210018,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/58134781705049914/58134781705049914.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/58134781705049914/58134781705049914.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66750,
      "choices": [
        {
          "id": 210021,
          "text": "TLC"
        },
        {
          "id": 210022,
          "text": "FEV1"
        },
        {
          "id": 210023,
          "text": "Forced expiratory flow 25% to 75% (FEF25–75%) or peak mid-maximal flow"
        },
        {
          "id": 210024,
          "text": "Forced vital capacity (FVC)"
        }
      ],
      "text": "A 50-year-old man smoking 20 bidi per day for last 15 years presented to OPD. Now he c/o occasion episodes of dyspnea on exertion. On examination-pallor absent, cyanosis absent, chest wall normal shape, no added sound. Cardiovascular system-normal. A provisional diagnosis of COPD is made. You order pulmonary function tests. Which of these becomes abnormal first in COPD?",
      "unique_key": "Q6225693",
      "question_audio": null,
      "question_video": null,
      "map_id": 34966193,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Forced expiratory flow 25% to 75% (FEF25–75%) or peak mid-maximal flow. In chronic obstructive pulmonary disease (COPD), the earliest detectable abnormality on pulmonary function tests is often a decrease in the forced expiratory flow at 25% to 75% of the forced vital capacity (FEF25-75%). This measurement reflects the flow of air in the smaller airways, which are more susceptible to narrowing and obstruction early in COPD. Since COPD primarily affects the small airways initially, this is the first parameter to show a decline before other more commonly measured parameters such as FEV1 or FVC become abnormal. A reduction in FEF25-75% is therefore a sensitive early indicator of small airway dysfunction in COPD. Incorrect Options: A. TLC (Total Lung Capacity): While total lung capacity (TLC) can be increased in advanced COPD due to air trapping, it is typically not the first abnormality seen in early stages. TLC may be normal in the early phases, and its increase tends to occur as the disease progresses, particularly in the later stages when hyperinflation develops. B. FEV1 (Forced Expiratory Volume in 1 second): FEV1 is a key diagnostic parameter in COPD, and its reduction occurs as the disease progresses, particularly when airway obstruction becomes more pronounced. However, FEV1 tends to be affected later in the disease process, following changes in FEF25-75%. A reduction in FEV1 is a hallmark of COPD, but it is not the first parameter to become abnormal. D. FVC (Forced Vital Capacity): FVC is a measure of the total amount of air a person can forcibly exhale after taking a deep breath. While it may be reduced in severe COPD due to airway obstruction and air trapping, it is usually not the earliest abnormality. FVC tends to remain normal in the early stages of COPD, and changes are generally seen after other parameters such as FEF25-75% or FEV1 are already abnormal.",
      "correct_choice_id": 210023,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24846881705127507/24846881705127507.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/24846881705127507/24846881705127507.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 66751,
      "choices": [
        {
          "id": 210025,
          "text": "Augmentation with alpha trypsin"
        },
        {
          "id": 210026,
          "text": "Home oxygen therapy"
        },
        {
          "id": 210027,
          "text": "Oral steroids"
        },
        {
          "id": 210028,
          "text": "Refer for lung transplantation"
        }
      ],
      "text": "A 68-year-old man a diagnosed case of COPD for last 10 years presented to respiratory clinic. He is on inhaled tiotropium, inhaled steroid, inhaled salmeterol and azithromycin. He has 2 admissions due to acute exacerbation in last one year. He has dyspnea on walking 100 metres. On examination- pallor absent, pedal edema absent, chest-bilateral ronchi, cardiovascular-normal, abdomen-soft. On examination-oxygen saturation 87%.FEV1/FVC-0.6,FEV1-50% of predicted. What will be next appropriate treatment for him",
      "unique_key": "Q8350155",
      "question_audio": null,
      "question_video": null,
      "map_id": 34240976,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Home oxygen therapy. This patient has a long history of COPD with frequent exacerbations and has been diagnosed with moderate to severe disease (FEV1 is 50% of predicted). His oxygen saturation is 87%, which is below the threshold for recommending home oxygen therapy (typically <88% saturation). Oxygen therapy is indicated for COPD patients who have chronic hypoxemia, as it helps improve survival, reduce symptoms, and prevent complications. In patients with an oxygen saturation <88% at rest or during exertion, long-term oxygen therapy can improve quality of life and reduce the risk of hospitalization and mortality. Therefore, home oxygen therapy is the next appropriate treatment for this patient. Incorrect Options: A. Augmentation with alpha-1 antitrypsin: Alpha-1 antitrypsin deficiency is a rare cause of COPD, and augmentation therapy with alpha-1 antitrypsin is used only in patients with this specific genetic deficiency. This patient does not have a history of alpha-1 antitrypsin deficiency, and there is no indication in the clinical presentation to suggest this as the cause of his COPD. Therefore, this option is not appropriate. C. Oral steroids: Oral steroids are typically used for managing acute exacerbations of COPD. While they can be effective in reducing inflammation during exacerbations, chronic use of oral steroids is not recommended due to potential side effects such as osteoporosis, diabetes, and increased risk of infections. This patient's current presentation does not warrant an oral steroid, as he is not experiencing an acute exacerbation. D. Refer for lung transplantation: Lung transplantation is considered for end-stage COPD patients with severe symptoms, frequent exacerbations, or organ failure who are not responsive to other treatments. However, this patient, despite his moderate to severe COPD and history of exacerbations, is not yet at a stage where lung transplantation would be indicated. He would need more severe disease progression and functional impairment for such a referral.",
      "correct_choice_id": 210026,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/17697881705049945/17697881705049945.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/17697881705049945/17697881705049945.m3u8",
      "question_images": [],
      "explanation_images": []
    }
  ]
}